9 Meters Biopharma is a clinical-stage company. Co.'s product development pipeline include: Vurolenatide, which is a long-acting glucagon-like peptide-1 receptor agonist that combines exenatide with a proprietary extended half-life technology for treatment of short bowel syndrome; Larazotide, which is being developed for the treatment of celiac disease; NM-102, which is a small molecule peptide that is being developed as a potential microbiome modulator and is undergoing an indication selection process; and NM-003, which is a proprietary long-acting glucagon-like peptide-2 agonist with improved serum half-life compared with short-acting versions. The NMTR stock yearly return is shown above.
The yearly return on the NMTR stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the NMTR annual return calculation with any dividends reinvested as applicable (on ex-dates).
|